acut
respiratori
distress
syndrom
ard
sever
form
inflammatori
lung
injuri
character
increas
vascular
permeabl
lung
clinic
ard
defin
presenc
sever
hypoxemia
bilater
opac
chest
imag
explain
presenc
cardiac
failur
volum
overload
communityacquir
pneumonia
cap
common
caus
ard
develop
outsid
hospit
respiratori
virus
increasingli
recogn
patient
sever
cap
ard
articl
review
epidemiolog
diagnosi
manag
adult
patient
sever
pneumonia
ard
caus
viral
respiratori
pathogen
improv
diagnost
test
particularli
multiplex
revers
transcript
polymeras
chain
reaction
rtpcr
assay
increas
recognit
respiratori
virus
caus
critic
ill
adult
although
studi
report
incid
ard
specif
caus
viral
pneumonia
epidemiolog
survey
adult
admit
intens
care
unit
icu
pneumonia
respiratori
failur
suggest
respiratori
virus
common
caus
sever
pneumonia
etiolog
pneumonia
commun
epic
studi
populationbas
surveil
cap
respiratori
virus
identifi
adult
admit
icu
radiograph
proven
pneumonia
prospect
observ
studi
consecut
patient
admit
icu
cap
hospit
kentucki
respiratori
virus
identifi
adult
retrospect
studi
patient
pneumonia
admit
singl
icu
south
korea
evid
viral
pneumonia
includ
patient
viru
identifi
bronchoalveolar
lavag
bal
seri
influenza
viru
rhinoviru
commonli
detect
respiratori
virus
identifi
approxim
case
viral
pneumonia
respect
preval
identifi
bacteri
coinfect
low
seri
mortal
relat
bacteri
viral
pneumonia
compar
epidemiolog
studi
shown
respiratori
virus
underappreci
caus
sever
cap
howev
result
studi
interpret
caution
sever
reason
first
virus
commonli
detect
patient
cap
vari
across
report
like
reflect
differ
patient
popul
season
geograph
locat
although
respiratori
virus
commonli
detect
critic
ill
patient
use
rtpcr
role
pathogenesi
sever
pneumonia
ard
less
clear
respiratori
virus
may
sole
caus
cap
ard
patient
may
risk
factor
predispos
patient
infect
organ
may
also
repres
concurr
upper
respiratori
tract
infect
colon
prolong
viral
shed
pathogenesi
pathogenesi
ard
patient
infect
respiratori
virus
incomplet
understood
adult
respiratori
viral
infect
mild
symptom
howev
viral
strain
associ
ard
pandem
influenza
viru
strain
ident
seen
mild
case
combin
variabl
host
factor
host
immun
respons
therefor
like
lead
develop
sever
pneumonia
ard
detail
review
patholog
mechan
implic
develop
ard
caus
respiratori
virus
beyond
scope
articl
sever
excel
review
topic
exist
respiratori
virus
initi
infect
nasal
bronchial
epithelium
point
entri
lead
respiratori
airway
alveolar
endotheli
injuri
elabor
cytokin
chemokin
recruit
innat
adapt
immun
cell
specif
cytokin
profil
vari
viru
converg
common
end
pathway
result
patholog
hallmark
ard
diffus
alveolar
damag
mechan
acut
lung
injuri
caus
viral
pathogen
import
clinic
implic
ard
result
inflammatori
host
respons
rather
viralmedi
injuri
antivir
therapi
alon
may
central
resolut
lung
injuri
diagnosi
ard
consid
patient
respiratori
viral
infect
hypoxemia
bilater
opac
chest
radiographi
unless
strong
clinic
suspicion
cardiogen
pulmonari
edema
volum
overload
criteria
diagnos
ard
refer
berlin
criteria
list
box
resourcelimit
set
diagnost
test
ensur
patient
meet
criterion
echocardiographi
arteri
blood
ga
analysi
may
possibl
situat
patient
hypoxemia
bilater
opac
chest
radiographi
consid
ard
unless
strong
clinic
suspicion
cardiogen
pulmonari
edema
volum
overload
present
diagnosi
respiratori
virus
made
use
isol
intact
viru
particl
cell
cultur
viral
antigen
detect
immunofluoresc
multiplex
rtpcr
avail
multiplex
rtpcr
provid
rapid
diagnosi
equal
better
sensit
specif
compar
viral
cultur
immunofluoresc
test
optim
site
sampl
depend
particular
respiratori
viru
incub
time
durat
symptom
patient
viral
pneumonia
bronchoscopi
safe
perform
combin
rtpcr
test
np
plu
bal
specimen
may
increas
diagnost
yield
compar
np
test
alon
addit
antivir
therapi
special
attent
paid
ventil
manag
support
care
similar
ard
caus
patient
requir
invas
mechan
ventil
treat
lowtidalvolum
strategi
target
mlkg
ideal
bodi
weight
case
sever
ard
consider
given
salvag
therapi
includ
prone
posit
paralyt
therapi
first
hour
follow
intub
although
noninvas
posit
pressur
ventil
tri
patient
ard
report
pandem
suggest
strategi
effect
patient
ard
caus
influenza
patient
sever
viral
infect
risk
secondari
bacteri
pneumonia
effect
viru
alon
risk
ventilatorassoci
pneumonia
prolong
mechan
ventil
invas
test
bronchoscopi
may
help
differenti
bacteri
coinfect
viral
pneumonia
alon
gener
empir
use
antibiot
therapi
patient
viral
pneumonia
avoid
may
increas
risk
antibiot
resist
subsequ
nosocomi
infect
use
intraven
corticosteroid
treatment
ard
gener
improv
outcom
patient
ard
relat
influenza
sever
acut
respiratori
syndrom
sar
adjunct
corticosteroid
improv
outcom
may
increas
risk
subsequ
nosocomi
infect
extracorpor
membran
oxygen
ecmo
gain
attent
influenza
pandem
sever
studi
report
low
mortal
patient
viral
ard
treat
modal
random
clinic
trial
compar
ard
treatment
ecmo
convent
care
cesar
trial
enrol
signific
proport
patient
influenza
howev
trial
sever
signific
methodolog
limit
particular
patient
ecmo
arm
treat
lowtidalvolum
ventil
strategi
compar
patient
convent
arm
retrospect
match
cohort
studi
patient
influenza
ard
mortal
patient
treat
ecmo
similar
propens
scorematch
control
treat
ecmo
past
year
respiratori
virus
attract
special
attent
high
proport
affect
patient
develop
critic
ill
ard
influenza
particularli
influenza
novel
coronavirus
middl
eastern
respiratori
syndrom
coronaviru
merscov
sar
coronaviru
sarscov
influenza
viru
frequent
describ
caus
viral
pneumonia
ard
adult
patient
influenza
viru
wide
varieti
host
antigen
subtyp
genet
divers
allow
viru
caus
annual
epidem
well
occasion
pandem
contrast
human
primari
host
influenza
b
viru
reli
mainli
genet
drift
propag
epidem
influenza
caus
season
epidem
winter
month
northern
south
hemispher
yearround
tropic
season
influenza
selflimit
infect
gener
popul
averag
annual
mortal
death
per
person
unit
state
season
influenza
account
estim
icu
admiss
yearli
adult
greater
year
age
resid
nurs
home
chronic
care
facil
pregnant
women
patient
chronic
medic
condit
immunecompromis
individu
obes
patient
higher
risk
sever
diseas
death
novel
strain
influenza
viru
detect
western
unit
state
mexico
quickli
spread
global
trigger
first
influenza
pandem
sinc
new
strain
caus
rang
clinic
syndrom
human
rang
mild
selflimit
ill
fulmin
pneumonia
ard
pandem
unit
state
approxim
hospit
excess
death
attribut
viru
icu
admiss
occur
hospit
adult
critic
ill
adult
die
risk
factor
poor
outcom
hospit
patient
age
less
year
pregnanc
especi
third
trimest
chronic
medic
ill
morbid
obes
immun
suppress
adult
influenza
viru
princip
clinic
syndrom
lead
ard
viral
pneumon
sever
hypoxem
respiratori
failur
sometim
accompani
shock
acut
renal
failur
syndrom
account
icu
admiss
pandem
radiograph
present
influenzainduc
ard
similar
ard
caus
comput
tomographi
scan
chest
influenza
classic
present
bilater
ground
glass
opac
area
alveolar
consolid
air
bronchogram
also
common
bacteri
viral
coinfect
common
particularli
patient
greater
year
age
complic
case
radiograph
find
typic
bacteri
pneumonia
alveolar
consolid
air
bronchogram
specif
enough
confirm
exclud
presenc
secondari
bacteri
pnuemonia
import
complic
influenza
critic
ill
patient
includ
venou
thromboembol
myocard
rhabdomyolysi
neurolog
manifest
confus
seizur
unconsci
encephalopathi
quadriparesi
enceph
neuraminidas
inhibitor
oseltamivir
zanamivir
mainstay
treatment
patient
influenza
earli
administr
antivir
therapi
may
decreas
progress
critic
ill
hospit
patient
typic
dose
oseltamivir
mg
twice
daili
howev
optim
dose
durat
oseltamivir
therapi
patient
ard
known
treatment
failur
shown
persist
influenza
detect
bal
sampl
critic
ill
adult
frequent
report
pandem
standarddos
oseltamivir
two
clinic
trial
compar
oseltamivir
mg
twice
day
mg
twice
day
show
signific
differ
clinic
outcom
proport
critic
ill
subject
enrol
trial
low
author
recommend
administr
higher
dose
oseltamivir
mg
twice
daili
day
treatment
influenza
dose
consid
patient
ard
relat
season
influenza
viru
zanamivir
avail
inhal
powder
intraven
therapi
zanamivir
gener
well
toler
extens
studi
critic
ill
adult
inhal
powder
avoid
patient
obstruct
airway
diseas
may
provok
bronchospasm
use
nebul
zanamivir
mechan
ventil
patient
associ
ventil
dysfunct
caus
lactos
carrier
pandem
sporad
report
oseltamivir
resist
report
caus
mutat
viral
neuraminidas
case
treat
intraven
zanamivir
evid
use
adjuv
corticosteroid
therapi
patient
influenza
infect
ard
larg
base
retrospect
studi
form
pandem
conflict
sever
studi
shown
increas
risk
nosocomi
infect
mortal
howev
studi
show
reduct
need
mechan
ventil
patient
hematopoiet
stem
cell
transplant
hospit
influenza
author
recommend
routin
use
corticosteroid
therapi
patient
influenza
pneumonia
ard
merscov
novel
lineag
b
coronaviru
first
identifi
saudi
arabia
sinc
sporad
case
outbreak
report
peopl
live
recent
travel
arabian
peninsula
merscov
infect
human
camel
via
receptor
present
noncili
bronchial
epitheli
cell
found
lower
respiratori
tract
median
incub
time
viru
day
long
day
merscov
suspect
patient
acut
febril
respiratori
ill
cap
live
recent
travel
arabian
peninsula
clinic
patient
merscov
present
rang
symptom
mild
upper
respiratori
symptom
sever
pneumonia
acut
renal
failur
ard
gastrointestin
complaint
includ
diarrhea
abdomin
pain
common
may
preced
onset
respiratori
symptom
one
case
seri
hospit
patient
laboratoryconfirm
case
merscov
need
intens
care
requir
mechan
ventil
report
mortal
case
seri
exce
hospit
patient
merscov
abnorm
chest
radiograph
cxr
comput
tomographi
find
consist
infecti
pneumonia
commonli
bilater
subpleur
groundglass
opac
although
lobular
consolid
also
describ
one
seri
microbiolog
evid
blood
respiratori
sampl
bacteri
viral
fungal
coinfect
found
patient
suggest
merscov
sole
organ
respons
respiratori
failur
ard
diagnosi
made
use
rtpcr
obtain
np
lower
respiratori
serum
specimen
patient
present
lower
respiratori
symptom
sever
ill
rtpcr
test
lower
respiratori
sourc
sputum
endotrach
aspir
bal
sensit
test
upper
respiratori
sourc
treatment
sarscov
support
date
prospect
clinic
trial
specif
treatment
intervent
glucocorticoid
use
adjuv
therapi
patient
sever
merscov
howev
clear
evid
practic
improv
outcom
combin
antivir
therapi
highdos
interferon
ribavirin
administ
shortli
inocul
merscov
rhesu
macaqu
show
decreas
viral
replic
radiograph
evid
pneumonia
retrospect
cohort
studi
patient
merscov
treat
combin
interferon
ribavirin
initi
median
day
diagnosi
found
reduc
mortal
compar
patient
treat
support
care
alon
merscov
antibodi
isol
memori
b
cell
human
patient
previous
infect
viru
antibodi
potenti
use
postexposur
prophylaxi
treatment
merscov
data
efficaci
human
patient
lack
sever
acut
respiratori
syndrom
coronaviru
sarscov
discov
outbreak
case
rapidli
progress
pneumonia
guoduong
provinc
china
total
case
sar
report
case
fatal
rate
anim
reservoir
sar
known
although
palm
civet
bat
implic
epidem
sar
spread
person
person
respiratori
droplet
lesser
extent
airborn
fecalor
transmiss
increas
transmiss
close
physic
proxim
sar
frequent
contract
health
care
worker
care
hospit
patient
pathogenesi
sar
incomplet
understood
like
relat
viral
infect
immunopatholog
injuri
function
receptor
sar
coronaviru
angiotensin
receptor
enzym
autopsi
studi
patient
die
sar
show
lung
intestin
tract
primari
site
infect
lung
histolog
often
show
diffus
alveolar
damag
vari
degre
organ
downregul
caus
viral
replic
play
protect
role
acut
lung
injuri
implic
develop
ard
patient
sar
clinic
manifest
sar
mild
prodrom
fever
myalgia
last
day
viral
replic
occur
respiratori
symptom
usual
cough
follow
dyspnea
hypoxemia
occur
second
week
ill
clinic
worsen
occur
time
decreas
viral
load
may
caus
immunopatholog
injuri
rather
direct
injuri
viru
dyspnea
may
progress
respiratori
failur
ard
need
mechan
ventil
radiograph
pattern
sar
nonspecif
commonli
present
illdefin
airspac
opac
groundglass
opac
progress
multifoc
airspac
opac
patient
develop
ard
diagnosi
sar
made
presenc
symptom
along
radiograph
abnorm
autopsi
consist
pneumonia
andor
ard
detect
viru
rtpcr
bodyfluid
sampl
cell
cultur
singl
sampl
detect
viral
antibodi
enzymelink
immunosorb
assay
andor
immunofluoresc
assay
sar
pandem
approxim
hospit
patient
develop
ard
manag
patient
sar
ard
primarili
support
lowtidalvolum
ventil
rescu
therapi
indic
strict
infect
control
measur
institut
includ
isol
affect
patient
rigor
use
mask
glove
gown
health
care
worker
prevent
humantohuman
transmiss
sever
ill
patient
sar
treat
highdos
ribavirin
corticosteroid
howev
expert
agre
therapi
littl
benefit
advers
effect
therapi
common
sarscov
dormant
sinc
end
outbreak
vaccin
develop
ongo
best
approach
remain
area
debat
season
respiratori
virus
identifi
adult
communityacquiredpneumonia
requir
icu
admiss
influenza
rhinovirus
human
rhinovirus
hrv
frequent
detect
virus
respiratori
syncyti
viru
rsv
coronavirus
parainfluenza
viru
piv
human
metapneumoviru
hmpv
adenoviru
also
commonli
report
whether
virus
sole
caus
pneumonia
ard
controversi
howev
bacteria
less
commonli
identifi
virus
even
invas
method
bronchoscopi
routin
use
test
caus
pneumonia
although
precis
frequenc
ard
caus
season
respiratori
virus
unknown
overal
frequenc
probabl
low
hrv
singlestrand
rna
viru
picornavirida
famili
common
caus
upper
respiratori
tract
infect
adult
children
hrv
also
one
commonli
identifi
virus
adult
admit
hospit
icu
cap
whether
rhinoviru
sole
caus
pneumonia
incident
find
risk
factor
bacteri
viral
coinfect
asymptomat
carriag
controversi
adult
radiograph
proven
cap
rhinoviru
identifi
frequent
patient
cap
compar
asymptomat
control
hrv
shown
trigger
cytokin
releas
lower
respiratori
epithelium
blood
suggest
potenti
pathogen
link
pneumonia
ard
rhinoviru
report
caus
ard
frequent
elderli
immunocompromis
adult
autopsi
find
bone
marrow
transplant
patient
suspect
hrv
pneumonia
show
find
consist
viral
pneumonia
includ
acut
chronic
interstiti
pneumon
diffus
alveolar
damag
hyalin
membran
consist
ard
among
patient
pneumonia
admit
icu
singl
center
south
korea
patient
hrv
pneumonia
requir
mechan
ventil
diffus
abnorm
cxr
suggest
ard
anoth
retrospect
analysi
hospit
adult
hrv
infect
immunocompromis
radiograph
evid
pneumonia
requir
icu
admiss
cohort
mortal
relat
hrv
rang
highest
among
patient
underli
immunocompromis
state
clear
role
antivir
therapi
critic
ill
adult
hrv
pneumonia
capsidbind
antihrv
agent
pleconaril
reduc
durat
uncompl
hrv
upper
respiratori
infect
day
howev
drug
approv
clinic
use
concern
drugdrug
interact
intranas
recombin
interferon
effect
prevent
hrv
cold
use
postexposur
prophylaxi
effect
treatment
establish
hrv
infect
studi
antivir
therapi
patient
hrv
critic
ill
need
rsv
envelop
paramyxoviru
import
caus
lower
respiratori
tract
infect
children
infect
peopl
age
rsv
subtyp
b
respons
human
diseas
rsv
epidem
occur
winter
month
overlap
season
influenza
adult
rsv
caus
rang
clinic
syndrom
includ
upper
respiratori
tract
infect
bronchiti
respiratori
failur
ard
adult
underli
cardiopulmonari
diseas
immunocompromis
state
hematopoiet
bone
marrow
transplant
year
age
risk
sever
infect
one
studi
elderli
hospit
adult
rsv
infect
admit
icu
requir
mechan
ventil
die
antivir
therapi
ribavirin
combin
human
intraven
immunoglobulin
ivig
corticosteroid
may
benefici
immunocompromis
adult
sever
pneumonia
caus
rsv
small
case
seri
suggest
oral
inhal
ribavirin
may
improv
morbid
mortal
hematopoiet
cell
transplant
recipi
nonrandom
studi
adult
lung
transplant
recipi
rsv
infect
suggest
combin
therapi
corticosteroid
ribavirin
effect
ribavirin
use
caution
patient
popul
inhal
formul
ribavirin
provok
bronchospasm
inhal
oral
ribavirin
potenti
teratogen
use
caution
pregnant
patient
pregnant
health
care
provid
avoid
contact
patient
receiv
aerosol
ribavirin
piv
singlestrand
envelop
rna
virus
paramyxovirida
famili
three
serotyp
caus
clinic
diseas
piv
seen
primarili
fall
winter
month
wherea
seen
spring
summer
season
although
piv
infect
gener
selflimit
hospit
icu
admiss
ard
occur
patient
underli
obstruct
lung
diseas
immunocompromis
host
may
suscept
retrospect
cohort
studi
hematopoiet
cell
transplant
patient
piv
infect
develop
pneumonia
associ
mortal
antivir
agent
shown
efficaci
piv
use
inhal
oral
intraven
ribavirin
treatment
piv
describ
case
report
howev
retrospect
studi
hematopoiet
cell
transplant
recipi
parainfluenza
receiv
inhal
ribavirin
combin
ivig
corticosteroid
show
benefit
term
either
viral
shed
mortal
investig
sialidas
fusion
protein
vitro
activ
piv
efficaci
drug
human
known
human
metapneumoviru
hmpv
envelop
negativesens
rna
viru
paramyxovirida
famili
discov
hmpv
infect
show
season
variat
typic
rsv
usual
mild
selflimit
hmpv
difficult
cultur
vitro
diagnosi
readili
made
use
rtpcr
np
lower
respiratori
tract
specimen
respiratori
failur
ard
caus
hmpv
report
adult
includ
resid
longterm
care
facil
sever
immunocompromis
patient
bone
marrow
transplant
acquir
human
defici
syndrom
case
seri
hospit
adult
hmpv
infect
requir
icu
admiss
develop
ard
anim
model
show
hmpv
infect
bronchial
epitheli
cell
lead
bronchial
hyperrespons
induc
proinflammatori
cytokin
includ
interleukin
il
interferon
alfa
histopatholog
chang
suggest
ard
includ
hyalin
membran
format
organ
pneumonialik
reaction
describ
openlung
transbronchi
biopsi
specimen
immunocompromis
patient
hmpv
identifi
bal
murin
model
also
shown
hmpv
increas
risk
sever
secondari
pneumococc
infect
similar
influenza
viru
antivir
therapi
hmpv
well
establish
sever
antivir
agent
sever
hmpv
investig
ribavirin
limit
viral
replic
downregul
cytokin
product
vivo
mous
modelsl
howev
uncontrol
case
seri
patient
hmpv
infect
treat
ribavirin
shown
consist
improv
outcom
monoclon
antibodi
hmpv
fusion
protein
seem
prophylact
therapeut
benefit
mous
model
studi
human
subject
current
lack
adenoviru
part
nonenvelop
famili
virus
doublestrand
dna
genom
true
incid
adenoviru
adult
difficult
estim
test
viru
routin
done
seri
adenoviru
found
icu
patient
addit
typic
lower
respiratori
symptom
adult
adenoviru
pneumonia
may
also
present
abdomin
complaint
diarrhea
neurolog
manifest
enceph
seizur
outbreak
sever
adenoviru
pneumonia
report
militari
recruit
resid
longterm
care
facil
immunocompromis
individu
although
rare
ard
report
immunocompet
adult
adenoviru
detect
rtpcr
np
lower
respiratori
stool
sampl
diagnosi
confirm
pcr
cell
cultur
detect
steril
site
blood
cerebrospin
fluid
tissu
biopsi
addit
support
care
patient
sever
adenoviru
pneumonia
ard
may
benefit
antivir
therapi
cidofovir
mononucleotid
analog
cytosin
reduc
viral
load
improv
clinic
symptom
patient
hematopoiet
stem
cell
transplant
invas
adenovir
diseas
compar
histor
control
case
seri
immunocompet
adult
adenoviru
pneumonia
administ
cidofovir
within
hour
diagnosi
surviv
radiograph
resolut
pneumonia
day
brincidofovir
lipidlink
deriv
cidofovir
current
phase
iii
clinic
trial
hematopoiet
stem
cell
transplant
patient
pool
human
ivig
high
level
neutral
antibodi
adenovirus
use
adjunct
therapi
retrospect
review
use
corticosteroid
immunocompet
patient
adenoviru
pneumonia
show
benefit
summari
respiratori
virus
common
caus
sever
pneumonia
ard
adult
advent
new
diagnost
technolog
particularli
multiplex
reactionpcr
increas
recognit
viral
respiratori
infect
critic
ill
adult
support
care
adult
ard
caus
respiratori
virus
similar
care
patient
ard
caus
although
antivir
therapi
avail
respiratori
viral
infect
research
need
determin
group
patient
would
benefit
